Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 9:51 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 997 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Inhibition Clear all
Completed No phase listed Observational Accepts healthy volunteers

Interaction of Right and Left Brain Hemispheres in Learning Precision Hand Movements

NCT00295568
View directory record Official record
Conditions
Interhemispheric Inhibition
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 40 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 18, 2026, 9:51 PM EDT
Not listed Early Phase 1 Interventional

Itraconazole as a Targeted Therapy for Inhibiting Hedgehog Pathway Signaling in Esophageal Cancer Patients

NCT02749513
View directory record Official record
Conditions
Esophageal Cancer
Interventions
Itraconazole
Drug
Lead sponsor
Dallas VA Medical Center
Federal
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 18, 2026, 9:51 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

AMPLIFI: Adaptive Modulation of Plasticity Through Lactate and Fitness Interventions

NCT06950060
View directory record Official record
Conditions
Stroke, Chronic, Aging, Cognitive Decline, Motor Dysfunction, Neuroplasticity
Interventions
High intensity cycling, Low-intensity cycling, Health education session, Moderate Intensity Aerobic Exercise
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 85 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 18, 2026, 9:51 PM EDT
Completed Phase 1Phase 2 Interventional

Safety Study of Oral Sodium Phenylbutyrate in Subjects With ALS (Amyotrophic Lateral Sclerosis)

NCT00107770
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
sodium phenylbutyrate
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
10
States / cities
Iowa City, Iowa • Lexington, Kentucky • Baltimore, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2010 · Synced Oct 18, 2026, 9:51 PM EDT
Terminated Phase 2 Interventional Results available

Trial of Ibrutinib Combined With Nivolumab or Cetuximab to Treat Recurrent/Metastatic HNSCC

NCT03646461
View directory record Official record
Conditions
Head and Neck Cancer, Squamous Cell Carcinoma of the Head and Neck
Interventions
Ibrutinib 560mg PO daily (Imbruvica), Cetuximab, Nivolumab
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 18, 2026, 9:51 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

The Effect of Gemfibrozil, Ketoconazole and Clarithromycin on the Amount of LY2409021 in the Bloodstream

NCT01836198
View directory record Official record
Conditions
Healthy Volunteers
Interventions
LY2409021, Gemfibrozil, Ketoconazole, Clarithromycin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 8, 2019 · Synced Oct 18, 2026, 9:51 PM EDT
Completed No phase listed Observational

A Real-World Study of Treatment Patterns, Tolerability and Effectiveness of CDK4/6 Inhibition in HR+, HER2-negative Metastatic Breast Cancer Patients

NCT07760714
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 120 Years
Enrollment
945 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 18, 2026, 9:51 PM EDT
Completed Phase 4 Interventional Results available

The Platelet Aggregation After tiCagrelor Inhibition and FentanYl Trial (PACIFY)

NCT02683707
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Removal of Fentanyl from peri-procedural analgesia, Fentanyl, Lidocaine, Midazolam
Other · Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 100 Years
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 7, 2018 · Synced Oct 18, 2026, 9:51 PM EDT
Recruiting Phase 1Phase 2 Interventional

The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function

NCT05972564
View directory record Official record
Conditions
Obesity, Metabolic Syndrome
Interventions
Empagliflozin 25 MG, Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 18, 2026, 9:51 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

The Study of Inflammation on Blood Glucose Levels in Obese People

NCT00258115
View directory record Official record
Conditions
Obesity
Interventions
salsalate
Drug
Lead sponsor
Joslin Diabetes Center
Other
Eligibility
18 Years to 30 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2003
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 15, 2018 · Synced Oct 18, 2026, 9:51 PM EDT
Completed Phase 1 Interventional Results available

Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade

NCT03493932
View directory record Official record
Conditions
Glioblastoma
Interventions
Nivolumab, BMS-986016
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
2
States / cities
Atlanta, Georgia • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 24, 2024 · Synced Oct 18, 2026, 9:51 PM EDT
Completed Phase 1 Interventional

Dendritic Cell Vaccine for Children and Adults With Sarcoma

NCT01803152
View directory record Official record
Conditions
Sarcoma, Soft Tissue Sarcoma, Bone Sarcoma
Interventions
Dendritic Cells Vaccine, Lysate of Tumor, Gemcitabine, Imiquimod, Leukapheresis
Biological · Drug · Procedure
Lead sponsor
Macarena De La Fuente, MD
Other
Eligibility
1 Year to 100 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 3, 2024 · Synced Oct 18, 2026, 9:51 PM EDT
Recruiting Phase 1 Interventional

PAS-004 in Patients With Advanced Solid Tumors

NCT06299839
View directory record Official record
Conditions
RAS Mutation, NF1 Mutation, RAF Mutation, Advanced Solid Tumors
Interventions
PAS-004 Capsules, PAS-004 Tablets
Drug
Lead sponsor
Pasithea Therapeutics Corp.
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
4
States / cities
Austin, Texas • Irving, Texas • San Antonio, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Oct 18, 2026, 9:51 PM EDT
Completed Phase 2 Interventional Results available

A Study of Vascular Endothelial Growth Factor (VEGF) Inhibition in Patients With Unilateral Upper Extremity Lymphedema Following Treatment for Cancer

NCT00827372
View directory record Official record
Conditions
Lymphedema
Interventions
Pazopanib
Drug
Lead sponsor
Kathy Miller
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 16, 2023 · Synced Oct 18, 2026, 9:51 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Functional Magnetic Resonance Imaging (fMRI) for the Study of Response Inhibition, and Face and Linguistic Processing in Autism

NCT00211783
View directory record Official record
Conditions
Autism, Asperger's Syndrome
Interventions
fMRI
Procedure
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 50 Years
Enrollment
71 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 28, 2012 · Synced Oct 18, 2026, 9:51 PM EDT
Withdrawn Phase 2 Interventional

Vactosertib with Durvalumab in Urothelial Carcinoma Failing Checkpoint Inhibition

NCT04064190
View directory record Official record
Conditions
Urothelial Carcinoma Recurrent, Advanced Urothelial Carcinoma
Interventions
Vactosertib(TEW-7197)/ Durvalumab
Drug
Lead sponsor
MedPacto, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
2
States / cities
San Francisco, California • Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Dec 9, 2024 · Synced Oct 18, 2026, 9:51 PM EDT
Completed Phase 1 Interventional

CP-868,596 And CP-868,596 Plus AG-013736 In Combination With Docetaxel In Advanced Solid Tumors

NCT00949624
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
CP-868,596, Docetaxel, AG-013736
Drug
Lead sponsor
Arog Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 19, 2012 · Synced Oct 18, 2026, 9:51 PM EDT
Completed Not applicable Interventional Results available

Enhancement of Brain Circuit of Inhibitory Control in Obese Patients Undergoing Gastric Banding

NCT01632280
View directory record Official record
Conditions
Obesity
Interventions
Transcranial Direct Current Stimulation (tDCS)
Device
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
20 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 7, 2019 · Synced Oct 18, 2026, 9:51 PM EDT
Completed Not applicable Interventional

Optimizing Exposure Therapy for Anxiety Disorders

NCT04048824
View directory record Official record
Conditions
Social Anxiety Disorder, Panic Disorder
Interventions
Inhibitory Learning-Based Exposure, Habituation-Based Exposure
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 65 Years
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 6, 2025 · Synced Oct 18, 2026, 9:51 PM EDT
Withdrawn Phase 3 Interventional

Gabapentin in Functional Dyspepsia Refractory to Proton Pump Inhibition

NCT01052896
View directory record Official record
Conditions
Functional Dyspepsia
Interventions
Gabapentin, Placebo
Drug
Lead sponsor
59th Medical Wing
Federal
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 1, 2020 · Synced Oct 18, 2026, 9:51 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Platform Study in Non-Small Cell Lung Cancer (NSCLC)

NCT06996782
View directory record Official record
Conditions
Advanced or Metastatic Non-small Cell Lung Cancer
Interventions
Rilvegostomig, Cisplatin, Carboplatin, Pemetrexed, Paclitaxel, Nab-paclitaxel, Ramucirumab
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
10
States / cities
Phoenix, Arizona • Santa Rosa, California • Jacksonville, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 18, 2026, 9:51 PM EDT
Completed Phase 2 Interventional Results available

Study of Benralizumab in People With Skin Side Effects Caused by Cancer Therapies

NCT04552288
View directory record Official record
Conditions
Solid Tumor, Solid Carcinoma, Solid Tumor, Adult, Hematologic Malignancy
Interventions
Benralizumab
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 85 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
5
States / cities
Basking Ridge, New Jersey • Commack, New York • Harrison, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 18, 2026, 9:51 PM EDT
Completed Phase 3 Interventional Results available

Open Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis

NCT04804605
View directory record Official record
Conditions
Atopic Dermatitis Eczema
Interventions
ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05%
Drug
Lead sponsor
Arcutis Biotherapeutics, Inc.
Industry
Eligibility
2 Years and older
Enrollment
1,220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
76
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Bryant, Arkansas + 64 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Oct 18, 2026, 9:51 PM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

RESTOR: PK/PD mTORi Inhibition in Older Adults

NCT06658093
View directory record Official record
Conditions
Aging
Interventions
Rapamycin, Everolimus, Placebo
Drug · Other
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
65 Years to 90 Years
Enrollment
194 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 18, 2026, 9:51 PM EDT